Radiprodil

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ChildrenPhase 1Seizure

55 competitors in Children

#DrugCompanyPhaseTrials

1

Promacta

GSK

Approved

22

Gleevec

Novartis

Approved

13

Oncaspar

SServier

Approved

24

Velcade

SShilpa Grover, MD, MPH

Approved

15

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

16

Byetta

AstraZeneca

Phase 3

17

Neurontin

VViatris Specialty LLC

Phase 3

28

Somavaratan

Novo Nordisk

Phase 3

19

Veklury

Gilead

Phase 2

110

Xyrem

Jazz Pharmaceuticals

Phase 2

1Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Phase 11 trial

Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants

Recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT07457229·40 enrolled

Interaction1 trial

Phase 1, Open-label, Drug-drug Interaction Study to Assess Effect Between Radiprodil and the Co-administered Drugs.

Completed·GGRIN Therapeutics, Inc.·Phase 1·NCT06975605·18 enrolled

Adult1 trial

Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults

Terminated·GGRIN Therapeutics, Inc.·Phase 1·NCT06965881·30 enrolled

Children1 trial

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

Active, not recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT05818943·24 enrolled

Infantile Spasms1 trial

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Terminated·UCB·Phase 2·NCT02829827·3 enrolled

4 more indications

Oral1 trial

Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers

Completed·UCB·Phase 1·NCT02647697·10 enrolled

Seizure1 trial

Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II

Recruiting·GGRIN Therapeutics, Inc.·Phase 1/2·NCT06392009·30 enrolled

GRIN-related Neurodevelopmental Disorder1 trial

A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Recruiting·GGRIN Therapeutics, Inc.·Phase 3·NCT07224581·100 enrolled

Unspecified1 trial

A Phase 1, Open-Label, 2-Part Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of a CYP3A4 Inducer (Carbamazepine) or Inhibitor (Itraconazole) With Radiprodil in Healthy Adult Participants

Active, not recruiting·GGRIN Therapeutics, Inc.·Phase 1·NCT07884734·36 enrolled

Details

Drug Info

Related News